



Vivaldi Biosciences Appoints Manfred Reiter, PhD as Senior Vice President, Manufacturing

April 28, 2017

Fort Collins, CO – Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing genetically attenuated live influenza vaccines for seasonal and pandemic influenza, today announced the appointment of Manfred Reiter, PhD as Senior Vice President, Manufacturing. Dr. Reiter has responsibility for Vero cell-based production of Vivaldi’s deltaFLU live attenuated influenza vaccines (LAIVs), including process optimization, scale-up, and manufacture in compliance with global quality standards. In the near-term, Dr. Reiter will lead production of a candidate deltaFLU LAIV for the company’s planned Phase 2 clinical program to demonstrate protection in vaccinated volunteers challenged with a strain not included in the vaccine. Demonstration of such cross-protection against heterologous (unmatched) strains would be a significant advantage over currently available influenza vaccines.

“Manfred Reiter brings to Vivaldi substantial pharmaceutical industry experience and technical expertise in production of human vaccines in Vero cell culture that will be invaluable in the scale-up, tech transfer, and GMP production of deltaFLU vaccines. We expect our advanced Vero cell manufacturing platform will provide significant advantages in terms of speed, scale-up, capacity, reliability, and cost versus egg substrate manufacturing, the standard method of influenza vaccine production. Manfred is an industry leader in process development and cell-based vaccine production. We are pleased he has joined the Vivaldi team,” said Thomas Muster, PhD, Chief Scientific Officer.

Dr. Reiter has more than 30 years of experience managing process development and manufacturing teams for the development of human vaccines and recombinant therapeutic proteins, including cell-based production with Vero and other platforms. He has substantial experience with technologies and processes utilized in pre-clinical, clinical, and commercial development of biologicals, including scale-up and technology transfer to contract manufacturing organizations (CMOs). Dr. Reiter’s career includes 14 years with Baxter Bioscience, initially as Director, Upstream Process Development, and then as Senior Director, Process Development, Vaccines & Therapeutics, with responsibility for a team of process scientists and engineers for process development, and clinical and commercial production of vaccines and therapeutic proteins. Prior to joining Vivaldi, Dr. Reiter was Vice President of Process Development & Manufacturing at Hookipa Biotech AG, managing process development and GMP cell-substrate production of viral and cancer vaccines. Dr. Reiter is an inventor on 25 vaccine and therapeutic protein patent families, with more than 700 international patent records.

About Vivaldi Biosciences Inc.

Vivaldi Biosciences Inc. is addressing the compelling need for more effective influenza vaccines with new-generation live attenuated influenza vaccines (LAIVs) based on the biology of influenza nonstructural protein 1 (NS1). Conventional influenza vaccines (“flu shots”) have reduced effectiveness when the vaccine strains are not well matched to circulating influenza strains, as is often the case.

Vivaldi's deltaFLU LAIVs are a new vaccine approach showing potential for superior protection, including cross-protection against unmatched or genetically drifted influenza strains. Administered as a nasal spray, deltaFLU LAIVs stimulate the body's production of interferon, achieving a natural adjuvant effect that stimulates the immune system's T cells and antibody-producing B cells. deltaFLU LAIVs have been evaluated successfully in three Phase 1 and one Phase 1/2 clinical trials, demonstrating a potent immune response including cross-neutralizing serum and mucosal antibodies, and safety advantages including absence of vaccine virus shedding. Vivaldi Biosciences Inc. is headquartered in Fort Collins, CO. Its European affiliate, Vivaldi Biosciences AG, is based in Vienna, Austria. Additional information about Vivaldi can be found at <http://www.vivaldibiosciences.com>.

Forward-Looking Statements

This release contains forward-looking statements relating to Vivaldi Biosciences Inc. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Contact

Bill Wick
Vivaldi Biosciences Inc.
Tel: +1 970 492 4365
info@vivaldibiosciences.com